DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.

Konrad Klinghammer,Thomas Gauler,Carmen Stromberger,Grzegorz Kofla,Maike de Wit,Johannes Gollrad,Izabella Rauer,Peter Martus,Inge Tinhofer,Volker Budach,Ulrich Keilholz,Susen Burock

DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.

2020

Konrad Klinghammer
Thomas Gauler
Carmen Stromberger
Grzegorz Kofla
Maike de Wit
Johannes Gollrad
Izabella Rauer
Peter Martus
Inge Tinhofer
Volker Budach
Ulrich Keilholz
Susen Burock

6574Background: DURTRERAD is a randomized phase II study evaluating feasibility and efficacy of durvalumab (anti-PD-L1) vs. durvalumab and tremelimumab (anti-CTLA-4) in combination with radiotherap...

Keywords:

Durvalumab
Tremelimumab
open label study
Physical therapy
Oncology
HPV Negative
Interim analysis
locally advanced
Medicine
Internal medicine
Radiation therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations